KR20140005081A - Composition comprising an hydroxychalcone compounds as an active ingredient for anti inflammatory activity - Google Patents

Abstract

The present invention relates to a composition for preventing or treating inflammation containing a hydroxychalcone compound as an active ingredient, and health functional food having an inflammation preventing or treating effect. The compound according to the present invention has anti-angiogenic activity in a chorioallantoic membrane model, has a higher anti-inflammatory effect than 5-ASA or a chalcone compound which is known as compounds having anti-inflammatory activities, and identifies the effect of treating inflammatory bowel disease which is one kind of inflammatory diseases. The hydroxychalcone compound of the present invention can be used as a pharmaceutical purpose for preventing and treating various inflammatory diseases, and as food for preventing and treating the inflammatory diseases.

Description

[0001] The present invention relates to an anti-inflammatory composition comprising an hydroxychalcone compound as an active ingredient,

The present invention relates to a composition for preventing or treating an inflammatory disease containing a hydroxychalcone compound as an active ingredient and a health functional food.

Inflammation is a mechanism to repair and regenerate the injured area when an invasion that causes physical changes such as physical action, chemical substance, bacterial infection, etc. is applied to a living body or tissue, and once the stimulus is applied, histamine, serotonin, Vascular active substances such as bradykinin, prostaglandin, and leukotriene are liberated, resulting in increased vascular permeability and inflammation. However, a persistent inflammatory reaction rather promotes mucosal damage, and in some cases leads to diseases such as cancer.

Macrophages are known to be involved in various host responses such as acquired immunity as well as innate immunity, and they are known to be involved in the maintenance of homeostasis. In the inflammatory reaction, NO (nitric oxide) and cytokine are produced and play an important role in biological defense in the early stage of infection . Lipopolysaccharide (LPS), also known as endotoxin, is present in the extracellular membrane of Gram-negative bacteria and is found in macrophages or monocytes such as RAW 264.7, in the presence of TNF-α, interleukin-6 (IL- RTI ID = 0.0 > IL-1 (3). ≪ / RTI > In addition, the formation of such inflammatory mediators leads to the process of converting arachidonic acid into prostaglandin and the formation of NO due to the activity of phospholipase A2. In the body inflammation process, inflammatory factors such as excess NO and prostaglandin E ₂ (PGE ₂ ) are formed by iNOS and COX-2. Among these, NO has various physiological functions such as body defense function, signal transduction function, neurotoxicity, and vasodilation. In general, the formation of NO plays an important role in killing bacteria or eliminating tumors, but NO produced by iNOS in the inflammatory state not only promotes inflammatory responses such as vascular permeability and edema, but also stimulates inflammation mediator biosynthesis, . PGE _{2 is} known to be deeply involved in the development of cancer, such as promoting inflammation, immune response, and angiogenesis.

The use of anti-inflammatory drugs has caused pain relief to date, and most of non-narcotic analgesics have also been used for the treatment of acute and chronic inflammatory diseases because of their anti-inflammatory effects. However, it is difficult to use it for long term due to side effects. As a result, the severity of side effects is too great for the current treatment methods, so it is essential and urgent to develop new and improved therapeutic agents.

 Inflammatory Bowel Disease (inflammatory bowel disease) refers to a disease that causes inflammation in the intestinal tract. Ulcerative colitis, Crohn's disease, Behcet's disease, intestinal tuberculosis, amoebic enteritis, radiation-induced enteritis, Refers to chronic idiopathic inflammatory diseases, ulcerative colitis and Crohn's disease. Ulcerative colitis is a disease in which mucous membranes or ulcers are formed continuously on the mucous membranes of the colon. . In addition, Crohn's disease is a disease in which lesions such as ulcers are generated discontinuously in any part of the digestive tract from the mouth to the anus. In addition to abdominal pain, diarrhea and stool, severe cases include fever, hemorrhage, weight loss, , And anemia. Both ulcerative colitis and Crohn's disease are chronic refractory diseases in which recurrence is repeated after the symptoms have improved temporarily. Although there is an indication that environmental factors such as genetic factors, immune disorders, and diet are involved in the pathogenesis of these diseases, the cause is still unclear.

In the past, the incidence of ulcerative colitis and Crohn's disease was known to be high in westerners, but recently, the number of patients has increased rapidly in Korea and other countries due to changes in lifestyle such as eating habits. However, there are reasons why it is unclear, and fundamental treatment is not established. Therefore, it is not a goal of complete treatment, but rather a drug which delays and alleviates the progress of symptoms and maintains this state for as long as possible. As medicines for such popular therapies, mainly aminosalicylic acid preparations, adrenocorticosteroids, immunosuppressants, TNF-a monoclonal antibodies and the like have been used, but various side effects have been reported. For example, sulfasalazine used frequently as an aminosalicylic acid preparation has been reported to have side effects such as nausea, vomiting, anorexia, rash, headache, hepatitis, leukocytosis, abnormal red blood cells, proteinuria and diarrhea. Prednisolone, an adrenocortical steroid, is used for oral administration, enema, suppository, intravenous injection, etc. However, adverse effects such as femoral head necrosis due to gastric ulcer or long-term use are strong. Infliximab, a TNF-a monoclonal antibody, was used to treat patients with Crohn's disease after being approved by the US FDA for the treatment of Crohn's disease in 1998. However, it has been reported that side effects such as decreased blood loss, drug-induced lupus, hepatitis B / tuberculosis . In addition, the US FDA warns physicians that the use of infliximab and other Tumor Necrosis Factor (TNF) inhibitors may increase the risk of lymphoma and other cancers. Therefore, there is an urgent need for the development of new inflammatory bowel disease treatments with superior efficacy, safety and fewer side effects than currently used inflammatory bowel disease treatments.

Korea Patent Publication No. 2011-0130546 Korea Patent No. 1050020

Accordingly, an object of the present invention is to provide a composition for preventing or treating an inflammatory disease containing a hydroxychalcone compound as an active ingredient.

Another object of the present invention is to provide a health functional food for preventing or ameliorating an inflammatory disease comprising a hydroxychronic compound and a pharmaceutically acceptable carrier.

In order to accomplish the above object, the present invention provides a process for producing 1- (2-hydroxyphenyl) -3-phenylpropenone, 1- (3-hydroxyphenyl) ) -3-phenylpropenone, (3-hydroxyphenyl) -1-phenylpropenone, 3- (2-hydroxyphenyl) -1-phenylpropenone, 3- (2-hydroxyphenyl) propene, 1- (2-hydroxyphenyl) -3- (3-hydroxyphenyl) propenone, 1- (3-hydroxyphenyl) propenone, 1- (3-hydroxyphenyl) propenone, 3- (3-hydroxyphenyl) propene, 3- (2-hydroxyphenyl) -1- Prevention or treatment of inflammatory diseases containing, as an active ingredient, a compound selected from 1- (4-hydroxyphenyl) propenone or 1,3-bis (4-hydroxyphenyl 1) propenone or a pharmaceutically acceptable salt thereof A pharmaceutical composition is provided.

In one embodiment of the present invention, the composition may be included at a concentration of 0.1 uM to 20 uM.

In one embodiment of the present invention, the inflammatory disease may be selected from the group consisting of gastritis, colitis, nephritis, hepatitis and inflammatory bowel disease.

In one embodiment of the present invention, the inflammatory bowel disease may be selected from the group consisting of Crohn's disease, bowel lesions associated with Behcet's disease, ulcerative colitis, hemorrhagic rectal ulcer, and ileus.

The present invention also relates to a process for the production of 1- (2-hydroxyphenyl) -3-phenylpropenone, 1- (3-hydroxyphenyl) Propenone, (3-hydroxyphenyl) -1-phenylpropenone, 3- (2-hydroxyphenyl) -1-phenylpropenone, 3- (2-hydroxyphenyl) propene, 1- (2-hydroxyphenyl) -3- (3-hydroxyphenyl) propenone, 1- (3-hydroxyphenyl) propenone, 1- (3-hydroxyphenyl) propenone, 3- (3-hydroxyphenyl) propene, 3- (2-hydroxyphenyl) -1- Which comprises a compound selected from 1- (4-hydroxyphenyl) propenone or 1,3-bis (4-hydroxyphenyl) propenone as an active ingredient for preventing or ameliorating an inflammatory disease.

In one embodiment of the invention, the food may be in the form of a powder, granules, tablet, capsule or drink.

 Compounds according to the present invention are more effective in inhibiting inflammation when compared to 5-ASA or chalcone compounds, which have anti-angiogenic activity and are known to inhibit existing inflammation in the villous membrane model, It is characterized by its therapeutic effect of inflammatory bowel disease. Therefore, the hydroxychalcone compound according to the present invention can be used not only for pharmaceutical use for the treatment and prevention of various inflammatory diseases, but also as a foodstuff for improving or preventing symptoms of inflammatory diseases.

Figures 1A and 1B show the inhibitory effect of compounds 10-15 according to the invention on VEGF-induced angiogenesis ( ^* P < 0.05 compared to the control group, ^# P < 0.05 compared to the VEGF- ),
Figures 2a and 2b illustrate the inhibitory effect of compounds 16-24 according to the invention on the angiogenesis induced by VEGF (compared with the control group ^{* P <0.05;# P <} 0.05 compared with VEGF- treated group ).
Figure 3 shows the inhibitory effect of compounds according to the present invention on TNF- [alpha] -induced inflammatory responses.
FIG. 4 shows the result of measuring the TNBS-induced inflammatory growth disease-induced animal model by treating the compound of the present invention and determining whether there is a change in body weight.
FIG. 5 shows the result of observation of the colon of the test animal after TNBS was administered for 5 days.
FIG. 6 shows the result of measuring the tissue weight after extracting the large intestine of the test animal after administering TNBS for 5 days.
FIG. 7 shows the results of measurement of MPO activity in the intestinal mucosa in order to examine the extent of infiltration of inflammatory cells as an index for intestinal inflammation.

The present invention provides 1- (2-hydroxyphenyl) -3-phenylpropenone, 1- (3-hydroxyphenyl) -3-phenylpropenone, 1- (4-hydroxyphenyl) -3-phenylpropenone , 3- (2-hydroxyphenyl) -1-phenylpropenone, 3- (3-hydroxyphenyl) -1-phenylpropenone, 3- (4-hydroxyphenyl) -1-phenylpropenone, 1, 3-bis (2-hydroxyphenyll) propenone, 1- (2-hydroxyphenyl) -3- (3-hydroxyphenyl) propenone, 1- (2-hydroxyphenyl) -3- (4 -Hydroxyphenyl) propenone, 1- (2-hydroxyphenyl) -1- (3-hydroxyphenyl) propenone, 1,3-bis (3-hydroxyphenyll) propenone, 1- (3 -Hydroxyphenyl) -3- (4-hydroxyphenyl) propenone, 3- (2-hydroxyphenyl) -1- (4-hydroxyphenyl) propenone, 3- (3-hydroxyphenyl)- Prevention or treatment of inflammatory diseases containing a compound selected from 1- (4-hydroxyphenyl) propenone or 1,3-bis (4-hydroxyphenyll) propenone or a pharmaceutically acceptable salt thereof as an active ingredient It is characterized by providing a pharmaceutical composition.

In order to verify this fact, the present inventors conducted the following experiment through one embodiment of the present invention. In order to confirm the anti-angiogenic effect in vivo, CAM analysis was performed. As a result, It was found that the angiogenesis was strongly inhibited, and the highest activity was observed especially in the compounds 19, 21 and 22 (see Table 1).

According to another embodiment, the inflammatory reaction induced by TNF-α is markedly inhibited by 5-ASA (20 mM) or chalcone (DPhP, 10 μM), which is known to inhibit the existing inflammation of the hydroxychalcone compound (See FIG. 3).

Furthermore, the present inventors produced an animal model inducing inflammatory bowel disease, which is a type of inflammatory disease, and confirmed that the hydroxychalcone compound can treat inflammatory bowel disease. As a result, 5-ASA, an active metabolite of sulfasalazine, And chalcone compound (see Figs. 4 to 7).

Thus, it was found that the hydroxychalcone compound can prevent and treat diseases caused by abnormally proliferated angiogenesis.

As used herein, the term &quot; a disease caused by angiogenesis &quot; refers to a tumor, a corneal ulcer, a macular degeneration associated with aging, diabetic retinopathy, proliferative vitreoretinopathy, immature retinopathy, ocular inflammation, keratoconus, Sjogren's syndrome, Osteoarthritis, osteoarthritis, septic arthritis, psoriasis, abnormal wound union, bone disease, proteinuria, abdominal aortic aneurysm disease, degenerative cartilage loss due to traumatic joint injury, nervous system degenerative diseases, cirrhosis, And is preferably at least one selected from the group consisting of inflammatory bowel disease, inflammatory bowel disease, corneal disease, arteriosclerosis, restenosis, central nervous system inflammatory disease, Alzheimer's disease, skin aging and cancer invasion and metastasis, Tumor, corneal ulcer, macular degeneration associated with aging, diabetic retinopathy, proliferative vitreoretinopathy, immature retinopathy, ocular inflammation, It comprises a weight cornea, Sjogren's syndrome, myopia ophthalmic tumor or corneal transplants geobujeung.

The hydroxychalcone compound of the present invention can treat diseases caused by angiogenesis, but more specifically, can be used as a composition for preventing or treating inflammatory diseases.

The types of inflammatory diseases that can be prevented or treated according to the present invention include, but are not limited to, gastritis, colitis, nephritis, hepatitis, and inflammatory bowel disease.

In addition, the compounds of the present invention may be prepared into pharmaceutically acceptable salts and solvates by methods conventional in the art.

As salts, acid addition salts formed by pharmaceutically acceptable free acids are useful. The acid addition salt is prepared by a conventional method, for example, by dissolving the compound in an excess amount of an acid aqueous solution and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. The molar amount of the compound and the acid or alcohol (e.g., glycol monomethyl ether) in water may be heated and then the mixture may be evaporated to dryness, or the precipitated salt may be subjected to suction filtration.

As the free acid, organic acids and inorganic acids can be used. As the inorganic acids, hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid and the like can be used. Examples of the organic acids include methanesulfonic acid, p- toluenesulfonic acid, acetic acid, trifluoroacetic acid, Citric acid, lactic acid, glycollic acid, gluconic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid and the like.

In addition, bases can be used to make pharmaceutically acceptable metal salts. The alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, it is preferable for the metal salt to produce sodium, potassium or calcium salt in particular, and the corresponding silver salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (for example, silver nitrate).

Pharmaceutically acceptable salts of the compounds of the present invention include salts of acidic or basic groups that may be present in the compounds unless otherwise indicated. For example, pharmaceutically acceptable salts include the sodium, calcium, and potassium salts of the hydroxy group, and other pharmaceutically acceptable salts of the amino group include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate rate, methane sulfonate (mesylate) and p - toluene sulfonate (tosylate) and a salt, the salt manufacturing method or manufacturing process known in the art &Lt; / RTI &gt;

Another object of the present invention is to provide a process for preparing a compound of the present invention which can be prepared by a synthetic method known in the art and can be chemically synthesized by the method shown in the following reaction formulas, no.

[Reaction Scheme 1]

Scheme 1. Synthesis of hydroxychalcones.

Reagents and conditions: (i) KOH (10 equiv) / NaOH (5 equiv), EtOH, 224 h, 20 ° C, 3694% yield; (ii) BF ₃ Et ₂ O (0.5 equiv), Dioxane, 2h, 20 ° C, 74% yield.

For example, EtOH aryl methyl ketone of the same molar amount of (aryl methyl ketone; acetophenone, 2 '/ 3' / 4'-hydroxyacetophenone, 6 (R 1 = a -d)) and aryl-methyl aldehyde (methyl aryl aldehyde; benzaldehyde , 2/3/4-hydroxy benzaldehyde, 7 (R2 = ad)) was added a 50% aqueous solution of KOH or NaOH and catalytic condensation ( Claisen - Schmidt condensation reaction.

The compounds of the present invention obtained by the above method strongly inhibited angiogenesis induced by the treatment of neovascularization inducers such as vascular endothelial growth factor in the chicken villi model, It can be used as a composition for treating and preventing inflammatory diseases.

The composition of the present invention contains 0.01 to 99% by weight of the compound, based on the total weight of the composition.

However, the composition is not limited thereto, and may vary depending on the condition of the patient, the type of disease, and the progress of the disease.

The compositions comprising the compounds of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.

The composition containing the compound according to the present invention may be formulated in the form of powders, granules, tablets, capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, external preparations, suppositories and sterilized injection solutions, Examples of carriers, excipients and diluents that can be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient, such as starch, calcium carbonate, sucrose, Or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.

The preferred dosage of the compound of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the compound is preferably administered at 0.01 mg / kg to 10 g / kg per day, preferably 1 mg / kg to 1 g / kg per day. The administration may be carried out once a day or divided into several doses. Therefore, the dose is not intended to limit the scope of the present invention in any aspect.

The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, including, for example, oral and rectal, or intravenous.

The present invention also relates to a process for the preparation of 1- (2-hydroxyphenyl) -3-phenylpropanone, 1- (3-hydroxyphenyl) Phenon, (3-hydroxyphenyl) -1-phenylpropenone, 3- (2-hydroxyphenyl) -1-phenylpropenone, 3- (2-hydroxyphenyl) propene, 1- (2-hydroxyphenyl) -3- (3-hydroxyphenyl) propenone, 1- (3-hydroxyphenyl) propenone, 1- (3-hydroxyphenyl) propenone, 3- (3-hydroxyphenyl) propene, 3- (2-hydroxyphenyl) -1- Which comprises a compound selected from 1- (4-hydroxyphenyl) propenone or 1,3-bis (4-hydroxyphenyl) propenone as an active ingredient for preventing or ameliorating an inflammatory disease.

The health functional food comprising the compound of the present invention can be used variously for medicines, foods and drinks for prevention and improvement of inflammatory diseases. Examples of foods to which the compound of the present invention can be added include various foods, beverages, gums, tea, vitamin complexes, health supplements and the like, and they can be used in powder, granule, tablet, have.

Food forms to which the compounds of the present invention can be added include various foods of candy, beverages, gums, tea, vitamin complexes, or foods that are health supplement foods.

The compounds of the present invention can be added to foods or beverages for the purpose of preventing and improving inflammatory diseases. At this time, the amount of the compound in the food or beverage may generally be from 0.01 to 15% by weight of the total food weight of the health food composition of the present invention, and the health beverage composition is preferably 0.02 to 10 g based on 100 ml, Can be added in a proportion of 0.3 to 1 g.

The health beverage composition of the present invention may contain various flavoring agents or natural carbohydrates as an additional ingredient, such as ordinary beverages, in addition to containing a mixture of the above-mentioned compounds as essential ingredients in the indicated ratios, have. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like Sugar, and sugar alcohols such as xylitol, sorbitol, and erythritol. Natural flavors (tau martin, stevia compounds (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and intermediates (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples. It will be apparent to those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited to these embodiments.

< Reference Example  1>

Preparation for experiment

Starting materials and reagents were purchased from Aldrich Chemical Co., Junsei or others and used without further purification. HPLC grade acetonitrile (ACN) and methanol were purchased from Burdick and Jackson, USA. Thin-layer chromatography (TLC) and column chromatography (CC) were performed on Kieselgel 60 F ₂₅₄ (Merck) and silica gel (Kieselgel 60,230-400mesh, Merck) were used, respectively, and all compounds with aromatic rings were visualized on TLC plates with UV light (both short wavelength and long wavelength). NMR spectrum was used for ¹ H-NMR and 62.5 MHz for Bruker AMX 250 (250 MHz, FT) and ¹³ C-NMR. Chemical shifts measured migration from TMS. (Chemical shifts ( ? ) In ppm and coupling constants ( J ) in Hz). Melting points were calibrated using an open capillary tube with an electrothermal 1A9100 digital melting point apparatus.

HPLC analysis was performed using two instruments (Shimadzu LC-10 AT pumps gradient-controlled HPLC system, Shimadzu system controller (SCL-10A VP) and photo diode array detector (SPD-M10A VP) The volume (10 μL) of the sample was measured under the constant condition (gradient dilution: 10% A in B for 50% to 100% in A, 100% to 50% in B for 150 min, flow rate: 1.0 mL / min, t 254 nm UV detection , mobile phase a was 20 mM ammonium formate (AF) treated double distilled water and B was fed to the column _{(X- Terra5μMreverse-phaseC 18 column (} 4.6ⅹ250 mm) in 20 mM AF process in water 90% ACN solvent Im) compound purity Is expressed as a percentage (%).

< Example  1>

General synthesis process

The following example compounds were synthesized according to the following methods A to C by the KOH / NaOH / BF ₃ -Et ₂ O catalytic condensation reaction ( Claisen- Schmidt condensation reaction).

1-1. Method A

To the solution of aryl methyl ketone (acetophenone, 2 '/ 3' / 4'-hydroxyacetophenone) and aryl methyl aldehyde (benzaldehyde, 2/3/4-hydroxy benzaldehyde) 10 eq.) Of 50% aqueous solution was added and stirred at 20 [deg.] C for 2-24 hours. The reaction mixture was neutralized with 6 M aqueous HCl solution (pH adjusted to 2), extracted with ethyl acetate, and washed with water and brine. And further purified by recrystallization or column chromatography to obtain pure solid compounds.

1-2. Method B

Was synthesized analogously to Method A, except that 6 M aqueous NaOH solution (5 eq) was used.

1-3. Method C

BF ₃ -Et ₂ O (0.5 equiv) was added to the same molar amount of aryl methyl ketone (4'-hydroxyacetophenone) and aryl methyl aldehyde (4-hydroxybenzaldehyde) in a high amount of dioxane And the mixture was stirred at 20 ° C for 2 hours. The reaction mixture was extracted with ethyl acetate, and washed with water and brine. Further purification by column chromatography gave pure solid compounds.

< Example  2>

1- (2- Hydroxyphenyl ) -3-phenylpropenone (1- (2- Hydroxyphenyl ) -3- 메틸 프로렌one , 10)

Hydroxyacetophenone (2.40 mL, 20.00 mmol) and benzaldehyde (2.02 mL, 20.00 mmol) were used in accordance with Method A of Example 1 to give 1- (2-Hydroxy- 3-phenylpropenone (2.72 g, 60.7%, 12.1 mmol).

mp 97.197.8 [deg.] C .;

R _f (ethylacetate / n- hexane 1: 2 v / v): 0.46

HPLC purity: 100%

^{1 H- NMR (250 MHz, CDCl} 3) δ 12.84 (s, 1H, 1-phenyl 2'-OH), 7.96 (d, J = 15.5Hz, 1H, CO-C = C H), 7.95 (dd, J = 8.1, 1.6Hz, 1H, 1-phenyl 6'-H), 7.70 (d, J = 15.5Hz, 1H, CO-C H = C), 7.70-7.66 (m, 2H, 3-phenyl H- 3, H-3, H-4, H-6), 7.51 (ddd, J = 8.6, 7.3, 1.6 Hz, 1H, H-5), 7.05 (dd, J = 8.4, 0.9 Hz, 1H, 1-phenyl 3'-H), 6.99 (ddd, J = 8.1, 7.2, 1.2 Hz 1H,

^{13 C- NMR (62.5 MHz, CDCl} 3) δ 193.72, 163.57, 145.48, 136.43, 134.54, 130.94, 129.64, 129.04, 128.66, 120.04, 119.97, 188.86, 118.63.

< Example  3>

1- (3- Hydroxyphenyl ) -3- Phenylpropenone  (1- (3- Hydroxyphenyl ) -3- 메틸 프로렌one , 11)

(3-hydroxyacetophenone, 4.08 g, 30.00 mmol) and benzaldehyde (3.03 mL, 30.00 mmol) were used in accordance with the method A of Example 1 to obtain 1- -Hydroxyphenyl) -3-phenylpropenone (5.90 g, 87.7%, 26.3 mmol).

mp 120.2120.6 DEG C .;

R _f (ethylacetate / n- hexane 1: 2 v / v): 0.35

HPLC purity: 100%

¹ H-NMR (250 MHz, CDCl ₃ ) ? 7.86 (d, J = 15.7 Hz, 1H, CO-C = C H ), 7.66-7.62 1-phenyl H-2), 7.60 (d, J = 7.8 Hz, 1H, 1-phenyl H-6), 7.55 (d, J = 15.7 Hz, 1H, CO-C H = C), 7.44-7.41 (dd, J = 8.0, 2.4 Hz, 1 H), 7.38 (t, J = 7.8 Hz, 1H, 1-phenyl H-4), 6.59 (br, 1H, 1-phenyl 3-OH).

^{13 C- NMR (62.5 MHz, CDCl} 3) δ 190.87, 156.43, 145.52, 139.44, 134.69, 130.73, 129.91, 128.97, 128.56, 121.87, 120.99, 120.50, 115.19.

< Example  4>

1- (4- Hydroxyphenyl ) -3- Phenylpropenone  (1- (4- Hydroxyphenyl ) -3- 메틸 프로렌one , 12)

Hydroxyacetophenone (2.72 g, 20.00 mmol) and benzaldehyde (2.02 mL, 20.00 mmol) were used according to the method A of Example 1 to obtain the title compound as a light yellow solid 3-hydroxyphenyl) -3-phenylpropenone (3.85 g, 86.1%, 17.2 mmol).

mp 180.0180.7 [deg.] C;

R _f (ethylacetate / n- hexane 1: 2 v / v): 0.40

HPLC purity: 100%

^{1 H-NMR (250 MHz,} DMSO- d 6) δ 10.46 (br, 1H, 1-phenyl 4-OH), 8.08 (d, J = 8.5Hz, 2H, 1-phenyl H-2, H-6) , 7.93 (d, J = 15.7Hz , 1H, CO-C = C H), 7.857.84 (m, 2H, 3-phenyl H-2, H-6), 7.70 (d, J = 15.6Hz, 1H , CO-C H = C) , 7.457.42 (m, 3H, 3-phenyl H-3, H-4, H-5), 6.90 (d, J = 8.5Hz, 2H, 1-phenyl H-3 , H-5).

¹³ C-NMR (62.5 MHz, DMSO- d ₆ ) δ 187.32, 162.48, 142.95, 135.10, 131.45, 130.56, 129.27, 129.12, 128.95, 122.29, 115.61.

< Example  5>

3- (2- Hydroxyphenyl )-One- Phenylpropenone  (3- (2- Hydroxyphenyl )-One- 메틸 프로렌one , 13)

(2- (2-hydroxybenzaldehyde, 2.09 mL, 20.00 mL) according to Method A of Example 1, acetophenone (2.33 mL, 20.00 mmol) Hydroxyphenyl) -1-phenylpropenone (3.95 g, 88.2%, 17.6 mmol).

mp 149.9150.6 [deg.] C .;

R _f (ethylacetate / n- hexane 1: 2 v / v): 0.37

HPLC purity: 98%

¹ H-NMR (250 MHz, DMSO- d ₆ ) ? 10.31 (br, IH, 3-phenyl 2 -OH), 8.108.06 d, J = 15.8Hz, 1H, CO-C = C H), 7.87 (d, J = 15.8Hz, 1H, CO-C H = C), 7.85 (dd, J = 7.3, 1.4Hz, 1H, 3 phenyl H-6), 7.687.52 (m, 3H, 1-phenyl H-3, H-4, H-5), 7.26 (dt, J = 8.2, 1.5 Hz, ), 6.94 (dd, J = 8.2, 0.8 Hz, 1H, 3-phenyl H-3), 6.89 (t, J = 7.2 Hz, 1H, 3-phenyl H-5).

^{13 C- NMR (62.5 MHz, DMSO-} d 6) δ 189.75, 157.51, 139.80, 138.13, 133.19, 132.37, 129.05, 128.96, 128.60, 121.57, 121.12, 119.68, 116.46.

< Example  6>

3- (3- Hydroxyphenyl )-One- Phenylpropenone  (3- (3- Hydroxyphenyl )-One- 메틸 프로렌one , 14)

Using acetophenone (1.16 mL, 10.00 mmol) and 3-hydroxybenzaldehyde (1.22 g, 10.00 mmol) according to Method A of Example 1 above, a light yellow solid 3- (3-hydroxyphenyl) -1-phenylpropenone (2.11 g, 94.1%, 9.4 mmol) was obtained.

mp 170.1170.9 [deg.] C;

R _f (ethylacetate / n- hexane 1: 2 v / v): 0.35

HPLC purity: 98%

¹ H-NMR (250 MHz, DMSO- d ₆ ) ? 9.67 (br, IH, 3-phenyl 3 -OH), 8.15-8.11 d, J = 15.6Hz, 1H, CO-C = C H), 7.697.53 (m, 3H, 1-phenyl H-3, H-4, H-5), 7.67 (d, J = 15.6Hz, 1H, CO-C H = C ), 7.337.24 (m, 2H, 3-phenyl H-5, H-6), 7.22 (br, 1H, 3-phenyl H-2), 6.87 (ddd, J = 7.7, 2.1, 1.0 Hz, 1H, 3-phenyl H-4).

^{13 C NMR (62.5 MHz, DMSO-} d 6) δ 189.45, 158.00, 144.53, 137.79, 136.13, 133.35, 130.12, 129.02, 128.72, 122.09, 120.07, 118.08, 115.50.

< Example  7>

3- (4- Hydroxyphenyl )-One- Phenylpropenone  (3- (4- Hydroxyphenyl )-One- 메틸 프로렌one , Manufacturing of 15)

3- (4-tert-butoxycarbonylamino) -thiazol-4-ylamine was obtained according to Method A of Example 1 using acetophenone (2.33 mL, 20.00 mmol) and hydroxybenzaldehyde (2.44 g, 20.00 mmol) Hydroxyphenyl) -1-phenylpropenone (3.78 g, 84.5%, 16.9 mmol).

mp 174.2175.0 DEG C .;

R _f (ethylacetate / n- hexane 1: 2, v / v): 0.34

HPLC purity: 95%

¹ H-NMR (250 MHz, DMSO- d ₆ ) ? 10.14 (br, IH, 3-phenyl 4-OH), 8.128.08 d, J = 8.6Hz, 2H, 3-phenyl H-2, H-6), 7.70 (d, J = 15.4Hz, 1H, CO-C = C H), 7.697.51 (m, 4H, 1- phenyl H-3, H-4, H-5, CO-C H = C), 6.84 (d, J = 8.6 Hz, 2H, 3-phenyl H-3, H-5).

¹³ C-NMR (62.5 MHz, DMSO- d ₆ ) δ 189.20, 160.41, 144.77, 138.16, 133.06, 131.29, 128.95, 128.56, 125.97, 118.66, 116.05.

< Example  8>

1,3- Bis (2-hydroxyphenyl) propene  (1,3- Bis (2- hydroxyphenyl ) propenone, 16)

Hydroxyacetophenone (1.80 mL, 15.00 mmol) and 2-hydroxybenzaldehyde (1.57 mL, 15.00 mmol) were used according to Method A of Example 1 to obtain a yellow solid 1 , 3-bis (2-hydroxyphenyl) propenone (2.98 g, 82.8%, 12.4 mmol).

mp 173174 [deg.] C;

R _f (ethylacetate / n- hexane 1: 2 v / v): 0.46

HPLC purity: 100%

^{1 H-NMR (250 MHz,} CDCl 3) δ 12.93 (s, 1H, 1-phenyl 2'-OH), 8.24 (d, J = 15.6Hz, 1H, CO-CH = C H), 7.96 (dd, J = 8.1, 1.3Hz, 1H, 1-phenyl H-6), 7.89 (d, J = 15.6Hz, 1H, CO-C H = CH), 7.64 (dd, J = 7.7, 1.3Hz, 1H, 3 phenyl H-6), 7.50 (td, J = 8.8,1.4 Hz, 1H, 1-phenyl H-4), 7.30 (td, J = 8.8, 1.5 Hz, , J = 8.4, 0.8Hz, 1H , 1-phenyl H-3), 7.00 (t, J = 7.3Hz, 1H, 1-phenyl H-5), 6.95 (td, J = 8.1, 1.0Hz, 3- phenyl H-5), 6.87 (d, J = 8.0 Hz, 1H, 3-phenyl H-3), 5.73 (s, 1H, 3-phenyl 2-OH).

¹³ C-NMR (62.5 MHz, CDCl ₃ ) δ 194.47, 163.52, 155.51, 141.00, 136.31, 132.05, 130.14, 129.82, 122.03, 121.26, 121.14, 120.14, 118.85, 118.55, 116.51.

< Example  9>

1- (2- Hydroxyphenyl ) -3- (3- Hydroxyphenyl ) Propenone (1- (2- Hydroxyphenyl ) -3- (3-hydroxyphenyl) propenone, 17)

(3.61 g, 30.00 mmol) and 3-hydroxybenzaldehyde (3.66 g, 30.00 mmol) were used in accordance with the method B of Example 1 to obtain the title compound as a yellow solid - (2-hydroxyphenyl) -3- (3-hydroxyphenyl) propenone (6.49 g, 90.2%, 27.0 mmol).

mp 180181 [deg.] C .;

R _f (ethylacetate / n- hexane 1: 2 v / v): 0.38

HPLC purity: 100%

^{1 H- NMR (250 MHz, DMSO-} d 6) δ 12.44 (s, 1H, 1-phenyl 2'-OH), 9.65 (s, 1H, 3-phenyl 3-OH), 8.23 (dd, J = 8.4 , 1.5Hz, 1H, 1-phenyl H-6), 7.96 (d, J = 15.5Hz, 1H, CO-CH = C H), 7.76 (d, J = 15.5Hz, 1H, CO-C H = CH 2H), 7.55 (td, J = 8.4, 1.3 Hz, 1H, 1-phenyl H-4), 7.34-7.26 phenyl H-2), 7.01-6.95 (m, 2H, 1-phenyl H-3, H-5), 6.90 (dt, J = 7.6,1.1 Hz, 1H, 3-phenyl H-4).

¹³ C NMR (62.5 MHz, DMSO- d ₆ ) δ 193.76, 161.94, 157.96, 145.21, 136.49, 135.93, 131.10, 130.16, 121.92, 121.07, 120.39, 119.41, 118.38, 117.91, 115.69.

< Example  10>

1- (2- Hydroxyphenyl ) -3- (4- Hydroxyphenyl ) Propenone (1- (2- Hydroxyphenyl ) -3- (4-hydroxyphenyl) propenone, 18)

2-hydroxyacetophenone (2.40 mL, 20.00 mmol) and 4-hydroxybenzaldehyde (2.44 g, 20.00 mmol) were used according to Method A of Example 1 to obtain a yellow solid - (2-hydroxyphenyl) -3- (4-hydroxyphenyl) propenone (1.91 g, 39.8%, 7.9 mmol).

mp 163 164 ° C;

R _f (ethylacetate / n- hexane 1: 1 v / v): 0.43

HPLC purity: 95%

^{1 H- NMR (250 MHz, DMSO-} d 6) δ 12.81 (br, 1H, 1-phenyl 2'-OH), 10.27 (br, 1H, 3-phenyl 4-OH), 8.26 (d, J = 7.2 Hz, 1H, 1-phenyl H -6), 7.89 (d, J = 15.7Hz, 1H, CO-CH = C H), 7.83 (d, J = 16.4Hz, 1H, CO-C H = CH), (D, J = 8.6 Hz, 2H, 3-phenyl H-2, H-6), 7.54 (td, J = 8.1, 1.0 Hz, 1H, 2H, 1-phenyl H-3, H-5), 6.86 (d, J = 8.4 Hz, 2H, 3-phenyl H-3, H-5).

¹³ C-NMR (62.5 MHz, DMSO- d ₆ ) ? 193.81, 162.35, 160.89, 145.95, 136.40, 131.82, 130.91, 125.80, 120.75, 119.31, 117.98, 117.86, 116.16.

< Example  11>

1- (2- Hydroxyphenyl ) -1- (3- Hydroxyphenyl ) Propenone (1- (2- Hydroxyphenyl ) -1- (3-hydroxyphenyl) propenone, 19)

(3-hydroxyacetophenone, 4.08 g, 30.00 mmol) and 2-hydroxybenzaldehyde (3.13 mL, 30.00 mmol) were used in accordance with the method B of Example 1 to obtain a green solid - (2-hydroxyphenyl) -1- (3-hydroxyphenyl) propenone (6.35 g, 88.2%, 26.4 mmol).

mp 173174 [deg.] C;

R _f (ethylacetate / n- Hexane 1: 1 v / v): 0.47

HPLC purity: 100%

^{1 H- NMR (250 MHz, DMSO-} d 6) δ 10.00 (br, 2H, 1-phenyl 3'-OH, 3-phenyl 2-OH), 8.02 (d, J = 15.8Hz, 1H, CO-CH = C H), 7.83 (dd , J = 8.1, 1.3Hz, 1H, 3-phenyl H-6), 7.79 (d, J = 15.8Hz, 1H, CO-C H = CH), 7.55 (d, J Phenyl H-6), 7.40 (t, J = 2.2 Hz, 1H, 1-phenyl H-2), 7.35 (t, J = 7.9 Hz, 1H, ), 7.26 (td, J = 8.5, 1.5 Hz, 1H, 3-phenyl H-4), 7.05 (ddd, J = 8.0, 2.4, 0.7 Hz, J = 8.2, 0.8 Hz, 1H, 3-phenyl H-3), 6.85 (t, J = 7.7 Hz, 1H, 3-phenyl H-5).

¹³ C-NMR (62.5 MHz, DMSO- d ₆ ) δ 189.66, 157.91, 157.46, 139.68, 139.58, 132.23, 130.08, 129.10, 121.58, 121.38, 120.26, 119.66, 119.56, 116.44, 114.73.

< Example  12>

1,3- Bis (3-hydroxyphenyl) propene  (1,3- Bis (3- hydroxyphenyl ) &lt; / RTI &gt; propenone, 20)

(3-hydroxyacetophenone, 4.08 g, 30.00 mmol) and 3-hydroxybenzaldehyde (3.66 g, 30.00 mmol) were used in accordance with the method B of Example 1 to obtain the yellow solid , 3-bis (3-hydroxyphenyl) propenone (5.90 g, 82.0%, 24.5 mmol) was obtained.

mp 226227 DEG C .;

R _f (ethylacetate / n- hexane 1: 1 v / v): 0.43

HPLC purity: 100%

^{1 H- NMR (250 MHz, DMSO-} d 6) δ 9.74 (br, 2H, 1-phenyl 3'-OH, 3-phenyl 3-OH), 7.77 (d, J = 15.6Hz, 1H, CO-CH = C H), 7.63 (d , J = 15.4Hz, 1H, CO-C H = CH), 7.62 (d, J = 7.6Hz, 1H, 1-phenyl H-6), 7.43 (s, 1H, 1 phenyl H-2), 7.35 (t, J = 7.9 Hz, 1H, 1-phenyl H-5), 7.30-7.23 (m, 2H, 1H, 3-phenyl H-2), 7.06 (dd, J = 8.0, 2.3 Hz, 1H, 1-phenyl H-4), 6.87 (d, J = 7.4 Hz, 1H,

^{13 C- NMR (62.5 MHz, DMSO-} d 6) δ 189.35, 157.97, 144.34, 139.24, 136.18, 130.15, 122.24, 120.55, 120.09, 119.83, 118.04, 115.46, 114.81.

< Example  13>

1- (3- Hydroxyphenyl ) -3- (4- Hydroxyphenyl ) Propenone (1- (3- Hydroxyphenyl ) -3- (4-hydroxyphenyl) propenone, 21)

Hydroxybenzaldehyde (2.44 g, 20.00 mmol) and 3-hydroxyacetophenone (2.72 g, 20.00 mmol) were used in accordance with the method B of Example 1 to obtain a yellow solid - (3-hydroxyphenyl) -3- (4-hydroxyphenyl) propenone (2.10 g, 43.8%, 8.7 mmol).

mp 245246 DEG C .;

R _f (ethylacetate / n- Hexane 1: 1 v / v): 0.42

HPLC purity: 99%

^{1 H- NMR (250 MHz, DMSO-} d 6) δ 9.94 (br, 2H, 1-phenyl 3'-OH, 3-phenyl 4-OH), 7.73 (d, J = 8.5Hz, 2H, 3-phenyl H-6), 7.63 (d, J = 17.5 Hz, 2H, CO-C H = C H ), 7.59 (d, J = 7.7 Hz, 1H, 1-phenyl H-2), 7.34 (t, J = 7.9 Hz, 1-phenyl H-5), 7.04 (dd, J = 8.0, 2.3 Hz, 6.83 (d, J = 8.4 Hz, 2H, 3-phenyl H-3, H-5).

¹³ C-NMR (62.5 MHz, DMSO- d ₆ ) δ 189.14, 160.36, 157.90, 144.57, 139.63, 131.23, 130.01, 125.99, 120.18, 119.61, 118.82, 116.05, 114.72.

< Example  14>

3- (2- Hydroxyphenyl ) -1- (4- Hydroxyphenyl ) Propenone (3- (2- Hydroxyphenyl ) -1- (4-hydroxyphenyl) propenone, 22)

Hydroxybenzophenone (2.72 g, 20.00 mmol) and 2-hydroxybenzaldehyde (2.09 mL, 20.00 mmol) were used according to the method A of Example 1 to obtain the title compound as a red solid - (2-hydroxyphenyl) -1- (4-hydroxyphenyl) propenone (1.74 g, 36.4%, 7.3 mmol).

mp 197198 ° C;

R _f (ethylacetate / n- hexane 1: 1 v / v): 0.33

HPLC purity: 97%

^{1 H- NMR (250 MHz, DMSO-} d 6) δ 10.32 (br, 2H, 1-phenyl 4'-OH, 3-phenyl 2-OH), 8.02 (d, J = 8.7Hz, 2H, 1-phenyl H-2, H-6) , 8.01 (d, J = 15.9Hz, 1H, CO-CH = C H), 7.84 (d, J = 15.8Hz, 1H, CO-C H = CH), 7.83 (d , J = 8.8Hz, 1H, 3 -phenyl H-6), 7.24 (td, J = 8.4, 1.4Hz, 1H, 3-phenyl H-4), 6.92 (d, J = 7.5Hz, 1H, 3- phenyl H-3), 6.89-6.81 (m, 3H, 3-phenyl H-5, 1-phenyl H-3, H-5).

^{13 C- NMR (62.5 MHz, DMSO-} d 6) δ 187.62, 162.16, 157.20, 138.37, 131.85, 131.14, 129.58, 128.70, 121.79, 121.12, 119.57, 116.36, 115.54.

< Example  15>

3- (3- Hydroxyphenyl ) -1- (4- Hydroxyphenyl ) Propenone (3- (3- Hydroxyphenyl ) -1- (4-hydroxyphenyl) propenone, 23)

Hydroxybenzaldehyde (2.44 g, 20.00 mmol) and 4-hydroxyacetophenone (2.72 g, 20.00 mmol) were used according to Method B of Example 1 to obtain the title compound as a pale yellow solid 3- (3-hydroxyphenyl) -1- (4-hydroxyphenyl) propenone (3.95 g, 82.3%, 16.4 mmol) was obtained.

mp 261262 [deg.] C;

R _f (ethylacetate / n- hexane 1: 1 v / v): 0.47

HPLC purity: 95%

^{1 H- NMR (250 MHz, DMSO-} d 6) δ 10.49 (br, 1H, 1-phenyl 4'-OH) 9.64 (br, 1H, 3-phenyl 3-OH), 8.06 (d, J = 8.7Hz , 2H, 1-phenyl H- 2, H-6), 7.83 (d, J = 15.6Hz, 1H, CO-CH = C H), 7.59 (d, J = 15.5Hz, 1H, CO-C H = 1H, 3-phenyl H-2), 6.89 (d, J = 8.7 Hz, 2H, 1 H), 7.29-7.23 (m, 2H, phenyl H-3, H-5), 6.85-6.82 (m, 1H, 3-phenyl H-4).

¹³ C-NMR (62.5 MHz, DMSO- d ₆ ) δ 187.36, 162.43, 157.94, 143.22, 136.40, 131.43, 130.10, 129.33, 122.13, 119.91, 117.74, 115.62, 115.37.

< Example  16>

1,3- Bis (4-hydroxyphenyl) propene  (1,3- Bis (4- hydroxyphenyl ) propenone , 24)

According to Method C of Example 1, 4-hydroxyacetophenone (2.72 g, 20.00 mmol) and 4-hydroxybenzaldehyde (3.66 g, 30.00 mmol) were used to obtain a yellow solid , And 3-bis (4-hydroxyphenyl) propenone (4.41 g, 74.4%, 18.3 mmol).

mp 226227 DEG C .; R _f (ethylacetate: n- hexane 1: 1 v / v): 0.35

HPLC purity: 99%

^{1 H- NMR (250 MHz, DMSO-} d 6) δ 10.21 (br, 2H, 1-phenyl 4'-OH, 3-phenyl 4-OH), 8.04 (d, J = 8.7Hz, 2H, 1-phenyl H-2, H-6) , 7.71 (d, J = 8.6Hz, 2H, 3-phenyl H-2, H-6), 7.68 (d, J = 14.3Hz, 1H, CO-CH = C H) , 7.62 (d, J = 15.5Hz , 1H, CO-C H = CH), 6.88 (d, J = 8.7Hz, 2H, 1-phenyl H-3, H-5), 6.83 (d, J = 8.5 Hz, 2H, 3-phenyl H-3, H-5).

¹³ C-NMR (62.5 MHz, DMSO- d ₆ ) δ 187.25, 162.13, 160.04, 143.39, 131.16, 130.96, 129.64, 126.20, 118.73, 115.99, 115.51.

< Reference Example  2>

Experimental materials and reagents, instrument analysis

Cortisone acetate was purchased from Aldrich Chemical Co. (St. Louis, Mo., USA), and vascular endothelial growth factor (VEGF) was purchased from Cheju, Korea vascular endothelial growth factor was purchased from R & D systems (Minneapolis, Minn., USA), and whatman filter disc was purchased from Whatman, UK.

< Experimental Example  1>

CAM  Analysis of the inhibitory effect of compounds on angiogenesis

Vivo test phase (in (Nguyen M et al., Microvascular (CAM)) analysis was performed to confirm the antiangiogenic effect in vivo Res . , 47, pp31-40, 1994).

On the 10th day, the first small hole was drilled through a hypodermic needle (Green Cross Medical Industry, Korea) at the air sac region, and the chicken pellet was incubated at 37 ° C and 55% A second hole was drilled in the flat part of the porridge that would open the window.

(CAM) was separated from the husk of the periantha by cutting air through the hole in the air sac, the first hole, and the region was cut with a grinding wheel (Multipro 395JA, Dremel, Mexico) cm ² I made a window of size.

Next, vascular endothelial growth factor (VEGF) was treated with cortisone acetate (3 mg / ml) in a Whatman filter disk # 1 (whatman, USA) , Or interleukin-8 (IL-8) at a concentration of 10 ng / CAM.

Individual disks were suspended in 10 μl of PBS containing VEGF or a control solvent and the disks were placed on growing CAMs. The filter discs were placed on the blood vessels through the window made and the compounds of Example 1 of the present invention were added locally to the CAMs after 30 minutes and the drug-treated CAMs were incubated for 3 days.

Three days after the drug treatment, the CAM part on which the filter disk was placed was removed and washed with a phosphate buffer solution. Then, a stereomicroscope (Stemi SV6 stereomicroscope, Carl Zeiss, Germany) and Image-Pro Plus software (Media Cybernetics, MD, USA) were used to measure the number of vascular branches and analyze the data.

As a result of this experiment, it was confirmed that the compounds according to the present invention strongly inhibited VEGF-induced angiogenesis in vivo (see Table 1), and blood vessel branch points were observed in the PBS-treated group And VEGF, respectively. Treatment of the compounds of the present invention against CAM significantly inhibited VEGF-induced angiogenesis in number and small blood vessel length after incubation (see Figures 1a, 1b, and 2a, 2b). In particular, compound 15 exhibited the most potent anti-angiogenic activity in vivo (66%) at 1 / CAM.

Compound 19 also exhibited the strongest inhibitory activity (89%) among the compounds, and compounds 21 and 22 similarly showed strong inhibitory activity (80% and 87%, respectively)

< Experimental Example  2>

Hydroxy Chalcone  Analysis of inflammation inhibitory effect of compounds

The following experiment was conducted to confirm whether the pharmacological effect of the chalcone compounds synthesized in the present invention was anti-inflammatory effect.

HT-29 human colon epithelial cells and U937 human mononuclear cells were used as a cellular model of inflammatory bowel disease.

First, HT-29 cells (American Type Culture Collections, Rockville, Mass., USA) were cultured in RPMI 1640 containing 10% fetal bovine serum (FBS), 1% penicillin / streptomycin and 2 mmol / L glutamine, The cells were cultured at 37 캜 in an atmosphere of air and 5% CO 2. In the following experiments, cells having a cell size of 36 or less were used. Cells were subcultured on a weekly basis using D-PBS (Dulbecco's phosphate buffered saline) containing 0.25% trypsin and 1% EDTA. The culture medium was changed every two days, allowed to confluent on a culture plate, subcultured in a 1: 5 ratio.

For experiments, cells were plated in plastic cell culture wells containing serum-containing medium and allowed to adhere for 24 hours. All experiments were then carried out in serum-free conditions.

Each of the cells was treated with 1 ml of the compound prepared in the above Example 1 hour before the stimulation of TNF- ?. 19 compound, and a stock solution of each compound dissolved in dimethylsulfoxide (DMSO) was used. At this time, the final maximum concentration of DMSO used in the test medium was made to be 0.1% or less. In addition, the cells treated with one group and TNF-α alone were pretreated with a test medium containing 0.1% DMSO. As a positive control, 5-ASA was used in 20 mM 5-ASA, Lt; RTI ID = 0.0 &gt; inflammatory &lt; / RTI &gt;

The adherence of u937 monocytes to HT-29 cells by TNF-α is a representative in vitro model of inflammatory bowel disease and is the onset of inflammation. Therefore, inhibition of TNF-α-induced monocyte adhesion to intestinal epithelial cells by drugs may inhibit enteritis, ie inflammatory growth disease. As a result of the above experiment, it was found that the inflammatory reaction in which u937 monocyte adhered to HT-29 cells was significantly induced by TNF-α. In the group treated with hydroxysticon compound 19 (10 μM) (20 mM) or chalcone (DPhP, 10 μM), which is known to have an activity of suppressing the reaction (see FIG. 3).

< Experimental Example  3>

Hydroxy Chalcone  Effect of Compound on Inflammatory Bowel Disease

&Lt; 3-1 > Preparation of inflammatory bowel disease animal model and treatment of the compound of the present invention

The present inventors conducted the following experiments on an animal model of inflammatory bowel disease to confirm whether the hydroxychalcone compound of the present invention has a therapeutic effect on inflammatory bowel disease. To prepare an animal model for inducing inflammatory bowel disease, the test animals were purchased from Samtaco Bio Korea at 7 weeks of age and were stabilized with a general solid diet for 2 days and then used in the experiment. During the experiment, And the temperature of the breeding room was maintained at 25 ± 1 ° C and the relative humidity at 50 ± 10%. Light management was controlled by a 12-hour light-dark cycle with an automatic light conditioner.

Five groups (control group, TNBS alone group, TNBS + 5-ASA 100 mg / kg group, TNBS + hydroxy group, and the like) were administered by randomized block design so as to have an average body weight of 180 ± 10 g Kg of TNBS + chalcone, 10 mg / kg of TNBS + chalcone, and 50 mg / kg of TNBS + hydroxystearin compound No. 19 in a dose of 10 mg / kg, Respectively. TNBS (trobencene sulfonic acid) is known to cause inflammatory bowel disease.

Twenty-four hour fasting animals were anesthetized with diethyl ether and 0.8 ml of 3% TNBS diluted in 50% (v / v) ethanol in the intestinal canal via an anal using a polyethylene syringe connected to a polyethylene catheter was slowly After injection, the test animals were allowed to stand for 60 seconds in an upright position to prevent 3% TNBS from leaking out into the anus. The control group was injected with vehicle (50% (v / v) ethanol) just as in the other experimental groups.

To investigate the effect of the drug, 24 hours after fasting, the drug was administered once per day at a dose of 1 mg / kg or 10 mg / kg of hydroxysterocon compound No. 19 to the peritoneal cavity for 5 days from the next day after TNBS treatment, The comparative test materials used 5-ASA and chalcone compounds, which are the active metabolites of sulfasalazine, the most well-known treatment for inflammatory bowel disease, as a positive control.

<3-2> Weight measurement

 All test animals were sacrificed 7 days after TNBS administration and the severity of visible ulcers and inflammatory bowel disease (colitis) was assessed by two investigators who did not participate in the experiment. The large intestine of the test animal was excised and the tissue between 5 and 6 cm from the anus was cut into 1 cm length, and the intestinal weight and MPO activity were measured and used for histological examination.

In addition, all the experimental animals were observed for weight change in each rat during fasting and TNBS administration using a digital mass meter.

In a model of colitis causing intestinal inflammation using 3% TNBS in rats weighing 180-190 g, the change in body weight was observed daily for 5 days on the basis of the weight before TNBS treatment. As a result, Similarly, the vehicle treated controls continued to gain weight and the TNBS group continued to lose weight and recovered slightly from day 5, but the weight was significantly reduced when compared to the normal group. In the group treated with the positive control 5-ASA 100 mg / kg, the body weight gradually recovered from the fourth day, and the body weight was increased compared to the TNBS alone group. After administration of 1 mg / kg of hydroxystone compound 19 after TNBS treatment, body weight reduction was observed until day 3, and gradually recovered from day 4, and the body weight was increased compared to the TNBS alone treatment group. The hydroxanthocon compound 19 showed a greater weight recovery than the 5-ASA, which is known as an agent for treating inflammatory bowel disease (see FIG. 4).

<3-3> Visual observation

After 5 days of drug administration, the present inventors extracted the large intestine and visually examined it. As a result, TNBS-treated testes showed swelling and hyperemia in the large intestine compared to the control group, and edema and congestion of the appendix were observed appear.

In the group treated with 5-ASA 100 ㎎ / ㎏ of the positive control group, gross symptoms and adhesion between other organs and colon were significantly suppressed compared with the group treated with TNBS alone.

On the other hand, the group treated with the hydroxysticon compound No. 19 of the present invention showed significantly reduced edema and hyperemia compared to the group treated with TNBS alone, and particularly, the hydroxysticon compound 19 was treated with 10 mg / kg In the case of one group, it was observed to be almost similar to that of the normal group without any treatment. Accordingly, the inventors of the present invention have found that the hydroxychalcone compound of the present invention can effectively suppress edema and hyperemia of the large intestine caused by inflammatory bowel disease, -ASA &lt; / RTI &gt; (see FIG. 5).

<3-4> Tissue weighing of test animals

As a result of measuring the tissue weights of the colon of the test animals, the weight of the intestine with edema was significantly increased in the TNBS alone group compared to the vehicle treated control group. In the group treated with 5-ASA 100 ㎎ / ㎏ of the positive control, the intestinal weight was significantly decreased as compared with the TNBS-treated group, and the hydroxysterocon compound 19 treated group showed more relieved symptoms than the control group (See FIG. 6).

<3-5> MPO ( myeloperoxidase ) activity  Measure

The present inventors measured the MPO activity in the intestinal mucosa in order to examine the extent of infiltration of inflammatory cells as an index for intestinal inflammation.

 MPO (myeloperoxidase) is an enzyme found mainly in neutrophils, and the activity of MPO in tissues is an indicator of neutrophil infiltration, which is an index of inflammatory response and correlates with intestinal damage by inflammatory colitis.

The present inventors used the MPO assay kit to measure the MPO activity. The colon tissues were washed with cold PBS and weighed. The lysis buffer (pH 7.4, 200 mM NaCl, 5 mM EDTA, 10 mM Tris, 10% glycerol) was added and homogenized for 30 seconds using a tissue homogenizer (Bio homogenizer M133, BIOSPEC PRODUCTS Inc. USA).

The homogenized sample was centrifuged twice at 1500 × g for 15 minutes to obtain a supernatant, and the supernatant was measured for MPO activity using an MPO ELISA kit (HK210, Hycult Biotechnology, Netherlands).

That is, 100 μl of the supernatant was added to 96 wells coated with anti-mouse MPO antibody, reacted at room temperature for 1 hour, and washed three times with wash buffer. 100 μl of the reconstituted tracer was added thereto, reacted at room temperature for 1 hour, washed three times, and 100 μl of streptavidin-peroxidase conjugate was added.

After reacting for 1 hour at room temperature, 100 μl of TMB substrate solution was added. After 30 minutes of the reaction, 100 μl of stop solution was added to stop the reaction and the absorbance was measured at 450 nm. The MPO activity was a value at which 1 μM of hydrogen peroxide was reduced in water for 1 minute at 25 ° C, The amount of MPO contained in 1 ml was calculated.

As a result, MPO activity was significantly higher in the TNBS-treated group than in the control group, and MPO activity was significantly decreased in the 5-ASA 100 mg / kg-treated group. MPO activity was lower in the 1 mg / kg administration group of hydroxysticonine compound 19 than in the TNBS alone treatment group. In particular, 1 mg / kg inhibited the MPO activity of the tissue better than 100 mg / kg of 5-ASA (See FIG. 7).

Hereinafter, formulation examples of the composition containing the compound of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described.

Formulation example  One. Sanje  Produce

Compound 19 ............................................. 200 mg

Lactose ................................................. 100 mg

Talc ................................................. .. 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

Formulation example  2. Preparation of tablets

Compound 21 ............................................ 200 mg

Corn starch ........................................... 100 mg

Lactose ................................................. 100 mg

Magnesium stearate .................................... 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

Formulation example  3. Preparation of capsules

Compound 22 ............................................ 200 mg

Crystalline cellulose ...................................... 3 mg

Lactose ............................................ 14.8 mg

Magnesium stearate ................................ 0.2 mg

The above components are mixed in accordance with a conventional method for producing a capsule, and filled in a gelatin capsule to prepare a capsule.

Formulation example  4. Preparation of injections

Compound 15 ............................................ 200 mg

Mannitol ............................................... 180 mg

Sterile sterilized distilled water for injection ................................. 2974 mg

Na ₂ HPO _{4 ,} 12H ₂ O .......................................... .26 mg

(2 ml) per ampoule in accordance with the usual injection method.

Formulation example  5. Liquid  Produce

Compound 19 ............................................ 200 mg

Isolation Party ............................................... 10 g

Mannitol ................................................. .5 g

Purified water................................................. Suitable amount

Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.

Formulation example  6. Manufacture of health food

Compound 21 ............................................ 1000 mg

Vitamin mixture ............................................

Vitamin A Acetate .................................... 70 ㎍

Vitamin E .............................................. 1.0 mg

Vitamin B1 ............................................ 0.13 mg

Vitamin B2 ............................................ 0.15 mg

Vitamin B6 .............................................. 0.5 mg

Vitamin B12 ............................................ 0.2 ㎍

Vitamin C ............................................... 10 Mg

Biotin ................................................. 10 [mu] g

Nicotinic acid amide ....................................... 1.7 mg

Folic acid ................................................. ..50 [mu] g

Calcium pantothenate .......................................... 0.5 mg

Mineral mixture ............................................

Ferrous sulfate ............................................ 1.75 mg

Zinc oxide .............................................. 0.82 mg

Magnesium carbonate ......................................... 25.3 mg

Potassium Phosphate ............................................... 15 mg

Secondary Calcium Phosphate ............................................ 55 mg

Potassium citrate ............................................. 90 mg

Calcium carbonate .............................................. 100 mg

Magnesium chloride ............................................. 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Formulation example  7. Manufacture of health drinks

Compound 22 ............................................ 1000 mg

Citric acid ............................................... 1000 mg

Oligosaccharides ............................................... 100 g

Plum concentrate ............................................... g

Taurine ................................................. ..1 g

Add purified water .................................. Total 900 ml

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, &Lt; / RTI &gt;

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

So far I looked at the center of the preferred embodiment for the present invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.

Claims (6)

1- (2-hydroxyphenyl) -3-phenylpropenone, 1- (3-hydroxyphenyl) -3-phenylpropenone, 1- (4-hydroxyphenyl) -3-phenylpropenone, 3- (2-hydroxyphenyl) -1-phenylpropenone, 3- (3-hydroxyphenyl) -1-phenylpropenone, 3- (4-hydroxyphenyl) -1-phenylpropenone, 1, 3-bis (2-hydroxyphenyll) propenone, 1- (2-hydroxyphenyl) -3- (3-hydroxyphenyl) propenone, 1- (2-hydroxyphenyl) -3- (4 -Hydroxyphenyl) propenone, 1- (2-hydroxyphenyl) -1- (3-hydroxyphenyl) propenone, 1,3-bis (3-hydroxyphenyll) propenone, 1- (3 -Hydroxyphenyl) -3- (4-hydroxyphenyl) propenone, 3- (2-hydroxyphenyl) -1- (4-hydroxyphenyl) propenone, 3- (3-hydroxyphenyl)- Prevention or treatment of inflammatory diseases containing a compound selected from 1- (4-hydroxyphenyl) propenone or 1,3-bis (4-hydroxyphenyll) propenone or a pharmaceutically acceptable salt thereof as an active ingredient Pharmaceutical composition for. The method of claim 1,
The compound is a pharmaceutical composition for the prevention or treatment of inflammatory diseases, characterized in that it is contained in a concentration of 0.1uM to 20uM. The method of claim 1,
The inflammatory disease is a gastroenteritis, colitis, nephritis, hepatitis and inflammatory bowel disease. The method of claim 3,
The inflammatory bowel disease is a pharmaceutical composition for preventing or treating inflammatory diseases, characterized in that selected from the group consisting of Crohn's disease, intestinal lesions associated with Behcet's disease, ulcerative colitis, hemorrhagic rectal ulcer and ileal cystitis. 1- (2-hydroxyphenyl) -3-phenylpropenone, 1- (3-hydroxyphenyl) -3-phenylpropenone, 1- (4-hydroxyphenyl) -3-phenylpropenone, 3- (2-hydroxyphenyl) -1-phenylpropenone, 3- (3-hydroxyphenyl) -1-phenylpropenone, 3- (4-hydroxyphenyl) -1-phenylpropenone, 1, 3-bis (2-hydroxyphenyll) propenone, 1- (2-hydroxyphenyl) -3- (3-hydroxyphenyl) propenone, 1- (2-hydroxyphenyl) -3- (4 -Hydroxyphenyl) propenone, 1- (2-hydroxyphenyl) -1- (3-hydroxyphenyl) propenone, 1,3-bis (3-hydroxyphenyll) propenone, 1- (3 -Hydroxyphenyl) -3- (4-hydroxyphenyl) propenone, 3- (2-hydroxyphenyl) -1- (4-hydroxyphenyl) propenone, 3- (3-hydroxyphenyl)- A health functional food for the prevention or improvement of inflammatory diseases comprising a compound selected from 1- (4-hydroxyphenyl) propenone or 1,3-bis (4-hydroxyphenyll) propenone as an active ingredient. The method of claim 5,
The food is a functional food for the prevention or improvement of inflammatory diseases, characterized in that the powder, granules, tablets, capsules or beverage form.

Images